Obesity is a chronic condition caused due to dysfunctional neurohormonal systems resulting in excessive weight gain, cardiovascular disease, and other comorbidities like diabetes, adiposopathy, and certain types of cancer. Obesity is a major health issue that requires safe and effective strategies to address it on a receptor level. Lorcaserin is a serotonergic agonist and specifically promotes the activity of the 5HT- 2C receptor. It was previously approved by the FDA for the chronic management of obesity in adults with BMI>30 kg/m2 or at least one obesity-related comorbidity.
But now the FDA is requesting the withdrawal of the drug due to major health risks associated with the drug. Drug Specifications Indication: It was issued as adjunctive therapy along with reduced-calorie diet and increased physical activity for long term weight management in adults. The initial body mass index…
